1 Min Read
Nov 8 (Reuters) - Novo Nordisk A/S : * FDA advisory panel acting chairperson says panel members generally agree that signal of cardiovascular risk was seen for Novo nordisk’s
degludec insulin, and that it “may or may not be real” risk
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.